Loading organizations...
§ Private Profile · Tokyo, Tokyo, Japan
Biotech firm developing nanoparticle RNA delivery using red blood cell membranes for gene therapy, targeting diseases like cancer.
Cranebio is a dual-headquartered biotechnology company based in London and Tokyo that develops nanoparticle-based RNA delivery systems using red blood cell membranes alongside diagnostic self-testing kits. The organization actively partners with large pharmaceutical firms and specialized gene therapy enterprises to facilitate targeted treatments for complex neurological conditions, cancer, and various infectious diseases. During recent preclinical trials, the company demonstrated that its proprietary nanoparticle technology is ten times more effective than traditional synthetic delivery methods when tested in animal models. To support its clinical development and commercialization efforts, Cranebio has raised approximately $1.68 million in early-stage funding from a syndicate of backers that includes Exor Ventures, the Norrsken accelerator, Charlie Songhurst, and Anindya Sen. The enterprise was officially founded in 2022 by Luca Bolondi and Sujaan Das following their participation in the Entrepreneur First program at Imperial College London.
Cranebio has raised $1.7M across 1 funding round.
Cranebio has raised $1.7M in total across 1 funding round.
Cranebio has raised $1.7M across 1 funding round. Most recently, it raised $1.7M Series A in October 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 6, 2023 | $1.7M Series A | — | Axil Capital, Nippon Venture Capital | Announced |
Cranebio has raised $1.7M in total across 1 funding round.
Cranebio's investors include Axil Capital, Nippon Venture Capital.